Pharmacological profile of 2-bromoterguride at human dopamine D 2, porcine serotonin 5-hydroxytryptamine 2A, and α 2C-adrenergic receptors, and its antipsychotic-like effects in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 1, 2013, Pages 57-68

  Jantschak, F ^a   Brosda, J ^a   Franke, R T ^a   Fink, H ^a   Moller D ^b   Hubner H ^b   Gmeiner, P ^b   Pertz, H H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMOTERGURIDE; 2 CHLOROTERGURIDE; 2 IODOTERGURIDE; ALPHA 2C ADRENERGIC RECEPTOR; ARIPIPRAZOLE; CYCLIC AMP; DOPAMINE 2 RECEPTOR; GUANOSINE 59 O (3 THIO)TRIPHOSPHATE; HISTAMINE H1 RECEPTOR; NEUROLEPTIC AGENT; PHOSPHATE; SEROTONIN 2A RECEPTOR; TERGURIDE; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPSYCHOTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; CONTROLLED STUDY; CORONARY ARTERY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOLECULAR DYNAMICS; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SMOOTH MUSCLE; SWINE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHO CELLS; CORONARY VESSELS; CRICETINAE; CRICETULUS; DOPAMINE AGONISTS; HEK293 CELLS; HUMANS; LISURIDE; MALE; MOTOR ACTIVITY; ORGAN CULTURE TECHNIQUES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D2; SWINE;

EID: 84884645940     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.205997     Document Type: Article

References (54)

1. Ahlenius S and Hillegaart V (1986) Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol Biochem Behav 24:1409-1415.
2. Arnt J and Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
3. Baldessarini RJ and Tarazi FJ (2006) Pharmacotherapy of psychosis and mania, in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. (Brunton LL, Lazo JS, and Parker KL, eds) pp 461-500, McGraw-Hill, New York.
4. Benkert O, Müller-Siecheneder F, and Wetzel H (1995) Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 5 (Suppl):43-53.
5. 2 receptors. J Pharmacol Exp Ther 302:381-389.
6. (2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype. J Biol Chem 276:28667-28675.
7. Cushing DJ and Cohen ML (1993) Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2- receptor heterogeneity. J Pharmacol Exp Ther 264:193-200.
8. (2C)-adrenoceptors in the human striatum. Synapse 62:508-515.
9. 0 G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138:775-786.
10. Geyer MA and Ellenbroek B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1071-1079.
11. Görnemann T, Hübner H, Gmeiner P, Horowski R, Latté KP, Flieger M, and Pertz HH (2008) Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-hydroxytryptamine2B and 5-hydroxytryptamine2A receptors. J Pharmacol Exp Ther 324:1136-1145.
12. 2B subtypes in a heterologous cell line. Mol Endocrinol 6:920-926.
13. Hertel P, Fagerquist MV, and Svensson TH (1999) Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2 adrenoceptor blockade. Science 286:105-107.
14. Howes OD and Kapur S (2009) The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 35:549-562.
15. (3) subtype. J Med Chem 43:756-762.
16. Jantschak F and Pertz HH (2012) Alpha2C-adrenoceptors play a prominent role in sympathetic constriction of porcine pulmonary arteries. Naunyn Schmiedebergs Arch Pharmacol 385:595-603.
17. Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, and Tiihonen J (2009) Addon mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res 108:245-251.
18. 2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 462:33-40.
19. Kekewska A, Görnemann T, Jantschak F, Glusa E, and Pertz HH (2012) Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells. J Pharmacol Exp Ther 340:369-376.
20. 2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA 95:7731-7736.
21. Koch M (2006) Animal Models of Neuropsychiatric Diseases, Imperial College Press, London.
22. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
23. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, and Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
24. Lazareno S and Birdsall NJ (1993) Estimation of antagonist Kb from inhibition curves in functional experiments: alternatives to the Cheng-Prusoff equation. Trends Pharmacol Sci 14:237-239.
25. Leucht S, Corves C, Arbter D, Engel RR, Li C, and Davis JM (2009) Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet 373:31-41.
26. 2-adrenoceptor antagonists. Trends Pharmacol Sci 21:198-199.
27. Litman RE, Su TP, Potter WZ, Hong WW, and Pickar D (1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168:571-579.
28. Löschmann PA, Horowski R, and Wachtel H (1992) Bromerguride-an ergoline derivative with atypical neuroleptic properties. Clin Neuropharmacol 15(Suppl 1): 263A-264A.
29. Marano M and Kaumann AJ (1976) On the statistics of drug-receptor constants for partial agonists. J Pharmacol Exp Ther 198:518-525.
30. 2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8:315-327.
31. 2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol 13:891-903.
32. Meltzer HY, Massey BW, and Horiguchi M (2012) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13:1572-1586.
33. 2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31: 1854-1863.
34. Natesan S, Reckless GE, Barlow KB, Nobrega JN, and Kapur S (2011) Partial agonists in schizophrenia-why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol 14:1165-1178.
35. 2-adrenoceptor. J Pharmacol Exp Ther 303:805-814.
36. 2, receptor subtypes. J Pharmacol Exp Ther 303: 815-822.
37. Nordquist RE, Risterucci C, Moreau JL, von Kienlin M, Künnecke B, Maco M, Freichel C, Riemer C, and Spooren W (2008) Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 54:405-416.
38. Olbrich R and Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21:389-390.
39. Olbrich R and Schanz H (1991) An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J Neural Transm 84:233-236.
40. 1 receptors. Naunyn Schmiedebergs Arch Pharmacol 374:215-222.
41. Porsolt RD, Moser PC, and Castagné V (2010) Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther 333:632-638.
42. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
43. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ, and Fremeau RT, Jr (1994) Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 21:133-149.
44. Semba J, Watanabe A, Kito S, and Toru M (1995) Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34:785-791.
45. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, and Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
46. Simpson EH, Kellendonk C, and Kandel E (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65:585-596.
47. 35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors. Br J Pharmacol 161:1238-1249.
48. Svensson K, Ekman A, Piercey MF, Hoffmann WE, Lum JT, and Carlsson A (1991) Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn Schmiedebergs Arch Pharmacol 344:263-274.
49. 2S receptors render it a unique antipsychotic. Eur J Pharmacol 515:10-19.
50. 3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions. J Med Chem 54: 2477-2491.
51. 3H]MK912 and subtype-selective drugs. Brain Res 770:261-266.
52. Van Rossum JM (1963) Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 143:299-330.
53. (2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633-641.
54. 2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10:191-202.